Calculate CHA₂DS₂-VASc score for stroke risk in atrial fibrillation. Guides anticoagulation decisions with annual stroke risk estimates.
The CHA₂DS₂-VASc Score Calculator estimates annual stroke risk in patients with non-valvular atrial fibrillation and helps organize anticoagulation decisions. It builds on CHADS₂ by adding vascular disease, age 65-74, and female sex to improve risk separation at the lower end of the scale.
Scores range from 0 to 9. Higher scores point to higher stroke risk and usually support a stronger case for anticoagulation, depending on the full clinical picture.
Use the CHA₂DS₂-VASc score to separate lower-risk atrial fibrillation patients from those who may benefit more clearly from stroke prevention. It helps balance stroke prevention against the risk of bleeding.
The score is also useful when comparing patients with similar CHADS₂ results, since it adds a few extra risk factors that can change the decision.
CHA₂DS₂-VASc = C (CHF, 1) + H (HTN, 1) + A₂ (Age ≥75, 2) + D (DM, 1) + S₂ (Stroke/TIA, 2) + V (Vascular, 1) + A (Age 65-74, 1) + Sc (Sex female, 1) Range: 0-9 for females, 0-8 for males Remember: Age ≥75 gets 2 points (not 1). Prior stroke/TIA gets 2 points.
Result: Score 3 — 3.2% annual stroke risk
Hypertension (+1) + Age 65-74 (+1) + Diabetes (+1) + Male sex (0) = CHA₂DS₂-VASc 3. Annual stroke risk ~3.2%. Anticoagulation is recommended per guidelines.
ESC 2020 guidelines recommend: Score 0 (males) or 1 (females, sex factor only) — no antithrombotic therapy. Score 1 (males) — OAC should be considered. Score ≥2 — OAC is recommended. The AHA/ACC guidelines are similar, with slightly different phrasing about the score 1 category.
Four DOACs are approved for AF stroke prevention: apixaban (ARISTOTLE), rivaroxaban (ROCKET AF), edoxaban (ENGAGE AF), and dabigatran (RE-LY). Meta-analyses show DOACs reduce stroke/systemic embolism by 19% and intracranial hemorrhage by 52% compared to warfarin. Apixaban showed the best safety profile in trials.
Recent research examines whether patients with very low CHA₂DS₂-VASc scores detected by wearable ECG monitoring benefit from anticoagulation. The relationship between AF burden (time in AF vs total monitoring time) and stroke risk is under active investigation, potentially refining treatment decisions beyond simple yes/no anticoagulation.
Last updated:
This calculator applies the CHA₂DS₂-VASc stroke-risk framework for non-valvular atrial fibrillation by assigning 1-point and 2-point weights to the standard clinical factors, then summing them into the usual total score. The page reports the total as a structured aid for discussing stroke prevention and anticoagulation, while keeping the weighted age and prior-stroke items explicit so the user can see how the total is built.
The output is not a stand-alone anticoagulation order set. Anticoagulant choice still depends on valve status, renal function, bleeding risk, patient preference, and other clinical factors, and female sex should not be treated as a reason for anticoagulation when it is the only point on the scale.
No. Female sex alone (score 1 in an otherwise zero patient) is considered "low risk" per guidelines. The sex factor is only relevant when other risk factors are present. ESC guidelines recommend viewing female sex as a "risk modifier" rather than an independent risk factor.
DOACs (apixaban, rivaroxaban, edoxaban, dabigatran) are preferred over warfarin for most patients with non-valvular AF based on superior efficacy, safety profile, and convenience. Warfarin remains first-line for mechanical heart valves and moderate-to-severe mitral stenosis.
Yes. Risk factors accumulate with age and comorbidities. A patient who is low-risk at age 50 may become high-risk by age 65-75. Annual reassessment is recommended, especially around age thresholds.
Yes. Stroke risk and anticoagulation recommendations are the same regardless of AF pattern (paroxysmal, persistent, or permanent). All AF types carry similar long-term stroke risk.
HAS-BLED estimates bleeding risk on anticoagulation. Both scores should be calculated together. A high HAS-BLED score does not necessarily contraindicate anticoagulation but identifies modifiable bleeding risk factors and indicates closer monitoring.
LAA closure devices (Watchman) are an alternative for patients with high stroke risk who cannot tolerate long-term anticoagulation. They are not first-line therapy and require careful patient selection.